Sangamo Therapeutics, Inc. (SGMOQ)
0.1662
0.00 (0.00%)
USD |
OTCM |
Sep 03, 16:00
Sangamo Therapeutics Research and Development Expense (Annual) : 112.67M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 112.67M |
| December 31, 2024 | 111.28M |
| December 31, 2023 | 230.46M |
| December 31, 2022 | 249.90M |
| December 31, 2021 | 230.82M |
| December 31, 2020 | 180.65M |
| December 31, 2019 | 145.92M |
| December 31, 2018 | 114.87M |
| December 31, 2017 | 65.73M |
| December 31, 2016 | 65.62M |
| December 31, 2015 | 67.13M |
| December 31, 2014 | 56.74M |
| December 31, 2013 | 36.98M |
| Date | Value |
|---|---|
| December 31, 2012 | 31.71M |
| December 31, 2011 | 32.10M |
| December 31, 2010 | 33.15M |
| December 31, 2009 | 28.98M |
| December 31, 2008 | 31.23M |
| December 31, 2007 | 25.56M |
| December 31, 2006 | 21.53M |
| December 31, 2005 | 11.42M |
| December 31, 2004 | 11.05M |
| December 31, 2003 | 10.19M |
| December 31, 2002 | 13.36M |
| December 31, 2001 | 15.51M |
| December 31, 2000 | 11.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sarepta Therapeutics, Inc. | 1.493B |
| Anixa Biosciences, Inc. | 5.071M |
| Vicapsys Life Sciences, Inc. | 0.0006M |